OBJECTIVE： To provide reference for improving the drug price regulation policy in China. METHODS： Literature research， system comparison and other methods were used to summarize the commonalities and characteristics of drug price regulation policy in Germany， Japan and Taiwan area of China， and the successful experience was learned. RESULTS & CONCLUSIONS： Drug price management in Germany， Japan and Taiwan area of China has their own characteristics. Germany conducted reference price system and new drug pricing mechanism， which was the first country to introduce the reference price system. Japan granted price premiums to innovative drugs， decreased pricing for generic drugs and adjusted drug price again. And Taiwan area of China classified and grouped differential pricing to encourage competition negotiation and regularly investigated drug prices and pricing. Germany， Japan and Taiwan area regard medicare pay price as core of drug price management， adopt comprehensive means to regulate the drug price， and pay attention to the monitoring and regular adjustment of market price as well. Price negotiation， pharmacoeconomics and multiple pricing methods are broadly used. Value-based drug pricing system is new trend of price policy reform. It can be used for reference to improve the drug price regulation system in China.